We are live on
!
Find out more
VEA
Virtus ETF Advisers Portfolio holdings
AUM
$215M
1-Year Est. Return
53.68%
This Fund
S&P 500
This Quarter
Est. Return
-14.02%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$270M
AUM Growth
+$46.4M
(+21%)
Cap. Flow
+$86.8M
Cap. Flow
% of AUM
32.16%
Top 10 Holdings %
Top 10 Hldgs %
7.48%
Holding
501
New
128
Increased
202
Reduced
102
Closed
67
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Realty Income
O
|
+$931K |
| 2 |
SK Telecom
SKM
|
+$871K |
| 3 |
Moderna
MRNA
|
+$825K |
| 4 |
ConocoPhillips
COP
|
+$786K |
| 5 |
PXD
Pioneer Natural Resource Co.
PXD
|
+$785K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Agnico Eagle Mines
AEM
|
+$1.83M |
| 2 |
BPMP
BP Midstream Partners LP Common Units representing Limited Partner Interests
BPMP
|
+$1.76M |
| 3 |
The Mosaic Company
MOS
|
+$928K |
| 4 |
STR
Sitio Royalties
STR
|
+$559K |
| 5 |
Gold Fields
GFI
|
+$512K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Real Estate | 18.55% |
| 2 | Healthcare | 17.07% |
| 3 | Materials | 11.98% |
| 4 | Financials | 11.43% |
| 5 | Energy | 8.64% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
376
Editas Medicine
EDIT
$411M
| $123K | 0.05% |
10,370
+4,945
| +91% | +$66.3K |
|
377
Prothena Corp
PRTA
$455M
| $123K | 0.05% |
4,523
+837
| +23% | +$24.5K |
|
|
AKRO
378
DELISTED
Akero Therapeutics
AKRO
| $122K | 0.05% |
12,882
+5,080
| +65% | +$53K |
|
379
Codexis
CDXS
$141M
| $122K | 0.05% |
11,691
+6,668
| +133% | +$83.6K |
|
|
KYNB
380
Kyntra Bio
KYNB
$28.5M
| $122K | 0.05% |
463
+1
| +0.2% | +$255 |
|
381
Arvinas
ARVN
$530M
| $121K | 0.04% |
2,880
+532
| +23% | +$26.7K |
|
|
TVRD
382
Tvardi Therapeutics
TVRD
$23.8M
| $121K | 0.04% |
369
+10
| +3% | +$3.51K |
|
383
Revolution Medicines
RVMD
$40B
| $120K | 0.04% |
6,169
-206
| -3% | -$4.01K |
|
|
CMPS
384
Compass Pathways
CMPS
$1.52B
| $119K | 0.04% |
10,986
+4,462
| +68% | +$45K |
|
385
Erasca
ERAS
$6.55B
| $119K | 0.04% |
21,337
+9,805
| +85% | +$64.2K |
|
|
ITOS
386
DELISTED
iTeos Therapeutics
ITOS
| $119K | 0.04% |
5,790
+1,629
| +39% | +$38.7K |
|
|
FLNA
387
Filana Therapeutics
FLNA
$43.5M
| $119K | 0.04% |
4,241
+942
| +29% | +$23.8K |
|
388
Vir Biotechnology
VIR
$1.48B
| $119K | 0.04% |
4,659
+1,285
| +38% | +$30K |
|
389
Immunovant
IMVT
$8.23B
| $118K | 0.04% |
30,146
+8,984
| +42% | +$38.8K |
|
390
AtaiBeckley Inc
ATAI
$2.65B
| $117K | 0.04% |
32,106
+16,637
| +108% | +$68K |
|
|
DAWN
391
DELISTED
Day One Biopharmaceuticals
DAWN
| $117K | 0.04% |
6,551
-2,335
| -26% | -$24.1K |
|
|
MRUS
392
DELISTED
Merus
MRUS
| $117K | 0.04% |
5,183
-330
| -6% | -$6.89K |
|
|
RXDX
393
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
| $117K | 0.04% |
4,152
-737
| -15% | -$21.4K |
|
394
Arbutus Biopharma
ABUS
$871M
| $116K | 0.04% |
42,675
+5,227
| +14% | +$13.4K |
|
|
DICE
395
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
| $116K | 0.04% |
7,482
+1,166
| +18% | +$20.1K |
|
396
Crinetics Pharmaceuticals
CRNX
$8.87B
| $115K | 0.04% |
6,180
-166
| -3% | -$3.31K |
|
397
Relmada Therapeutics
RLMD
$546M
| $115K | 0.04% |
6,068
-2,448
| -29% | -$53.4K |
|
398
Precigen
PGEN
$1.93B
| $114K | 0.04% |
85,000
+41,072
| +93% | +$60.9K |
|
399
TG Therapeutics
TGTX
$8.53B
| $114K | 0.04% |
26,935
+16,994
| +171% | +$106K |
|
|
CERE
400
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
| $113K | 0.04% |
4,259
-957
| -18% | -$27.2K |
|
Similar funds
NCM
SSA
LIWM
VFG
IAM
1M
GC
ALS
Virtus ETF Advisers's Q2 2022 Portfolio in Review
As of Q2 2022, Virtus ETF Advisers held 501 positions worth $270M, up 21% from $223M the previous quarter. Its ten largest holdings account for 7.5% of the portfolio.
Virtus ETF Advisers deployed $86.8M of net new capital in Q2 2022, opening 128 new positions and adding to 202 existing holdings. Its largest new stake was ConocoPhillips: 7,627 shares worth $685K.
By sector, the portfolio is most concentrated in Real Estate at 19% of assets, down from 20% a quarter earlier, followed by Healthcare and Materials.
On the sell side, the largest reduction was Agnico Eagle Mines, an estimated $1.83M trimmed.
- Virtus ETF Advisers's largest Q2 2022 buy was ConocoPhillips: 7,627 shares worth $685K.
- Virtus ETF Advisers added most to Realty Income in Q2 2022, an estimated $931K increase.
- Virtus ETF Advisers's biggest Q2 2022 reduction was Agnico Eagle Mines, cutting an estimated $1.83M.
- Virtus ETF Advisers fully exited BP Midstream Partners LP Common Units representing Limited Partner Interests in Q2 2022, selling an estimated $1.76M.
- Virtus ETF Advisers's ten largest holdings make up 7.5% of its $270M portfolio in Q2 2022.
- Virtus ETF Advisers opened 128 new positions and closed 67 in Q2 2022.
- Virtus ETF Advisers's portfolio value rose 21% quarter-over-quarter to $270M.
Based on Virtus ETF Advisers's 13F filing for Q2 2022, filed 12 Aug 2022.